TNBC accounts for 10–20% of diagnosed breast cancers and is characterized by the negative expression of progesterone receptor (PR), estrogen receptor (ER), and human epidermal growth factor receptor 2 (HER2) (1). This evidence concerns the gene ESR1 and breast cancer.